- Home
- DFIN vs MIRM Comparison
DFIN vs MIRM Comparison
Compare DFIN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DFIN | MIRM |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 5.7B |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DFIN | MIRM |
|---|---|---|
| Price | $38.82 | $99.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $61.50 | ★ $119.85 |
| AVG Volume (30 Days) | 279.7K | ★ 1.0M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $963,000,000.00 | $19,138,000.00 |
| Revenue This Year | $4.98 | $26.22 |
| Revenue Next Year | $3.87 | $22.04 |
| P/E Ratio | $30.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.07 | $43.40 |
| 52 Week High | $66.25 | $114.99 |
Technical Indicators
Market Signals| Indicator | DFIN | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 31.13 | 49.75 |
| Support Level | $37.07 | $97.49 |
| Resistance Level | $55.10 | $107.51 |
| Average True Range (ATR) | 1.74 | 6.00 |
| MACD | -0.20 | -0.94 |
| Stochastic Oscillator | 20.90 | 27.72 |
Price Performance
Historical ComparisonAbout DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.